AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24740137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexibuprofen and Ibuprofen
Number of subjects: 489
Study 22441743 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg
Number of subjects: 828
Study 22441743 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg
Number of subjects: 828
Study 22441743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 828
Study 19114803 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat or sibutramine combined with dietary modification
Number of subjects: 42
Study 19114803 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine or protein supplementation
Number of subjects: 42
Study 19114803 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet lower in fat
Number of subjects: 42
Study 19114803 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to physical activity routines
Number of subjects: 42
Study 19114803 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged contact with participants
Number of subjects: 42
Study 19114803 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 42
Study 19114803 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 42
Study 18690278 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic medial branch blocks with bupivacaine (Group I)
Number of subjects: 48
Study 18690278 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic medial branch blocks with bupivacaine and non-particulate betamethasone (Group II)
Number of subjects: 48
Study 15942203 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute fasting hyperglycemia
Number of subjects: 10
Study 15942203 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemic hyperinsulinemia
Number of subjects: 10
Study 15942203 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 10
Study 12271721 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's live influenza vaccine (LIVI)
Number of subjects: 2486
Study 12271721 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult live influenza vaccine (LIVII)
Number of subjects: 2486
Study 12271721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2486
Study 12271721 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines (LIVI and LIVII)
Number of subjects: 2486
Study 10099908 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin
Number of subjects: 202
Study 10099908 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 202
Study 7769082 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (after mifepristone pre-treatment)
Number of subjects: 70
Study 7769082 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (vaginal route)
Number of subjects: 70
Study 2186323 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acylaminopenicillin plus aminoglycoside
Number of subjects: 1260
Study 2186323 — intervention group
Group type: EXPERIMENTAL
Intervention: Third‐generation cephalosporin plus aminoglycoside
Number of subjects: 1260
Study 2186323 — intervention group
Group type: EXPERIMENTAL
Intervention: Double beta lactam therapy
Number of subjects: 1260
Study 2186323 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin or all three substances from phase I
Number of subjects: 1260
Study 2186323 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B plus 5‐flucytosine and rifampin
Number of subjects: 1260
Study 2186323 — intervention group
Group type: COMPARATOR
Intervention: Continuation of the double beta lactam regimen or additional imipenem/cilastatin
Number of subjects: 1260
Study 298350 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 0
Study 298350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 298350 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine and Placebo
Number of subjects: 0
Study 31519284 — intervention group
Group type: EXPERIMENTAL
Intervention: WEACURE® (500 mg of Jadwar root powder)
Number of subjects: 64
Study 31519284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 28424257 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-source food (ASF) supplement (mean: 144 kcal, 8.9 mg Fe, 2.7 mg Zn, 1050 μg retinoic acid equivalent vitamin A, and 5.5 μg vitamin B-12)
Number of subjects: 117
Study 28424257 — intervention group
Group type: COMPARATOR
Intervention: Control snack (mean: 150 kcal, 2.0 mg Fe, 0.9 mg Zn, 0 μg retinoic acid equivalent vitamin A, and 0 μg vitamin B-12)
Number of subjects: 117
Study 28424257 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-source food (ASF) supplement
Number of subjects: 117
Study 24809429 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplementation (ONS) - 2 servings (460 mL) daily providing 432 kcal, 16 g protein, and 28 micronutrients for 12 weeks
Number of subjects: 212
Study 24809429 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplementation (ONS)
Number of subjects: 212
Study 24809429 — intervention group
Group type: COMPARATOR
Intervention: Dietary counselling (control)
Number of subjects: 212
Study 24229360 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 250 mg 3 times a week
Number of subjects: 84
Study 24229360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 21349111 — intervention group
Group type: EXPERIMENTAL
Intervention: comb-NBUVB (NBUVB therapy with daily application of antimicrobial gel)
Number of subjects: 10
Study 21349111 — intervention group
Group type: COMPARATOR
Intervention: mono-NBUVB (NBUVB therapy without antimicrobial gel)
Number of subjects: 10
Study 21349111 — intervention group
Group type: EXPERIMENTAL
Intervention: NBUVB treatment (both comb-NBUVB and mono-NBUVB)
Number of subjects: 10
Study 19583608 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG algorithm group (n = 114)
Number of subjects: 224
Study 19583608 — intervention group
Group type: COMPARATOR
Intervention: Clinician-directed transfusion group (n = 110)
Number of subjects: 224
Study 17407593 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine dependent individuals who were successful in abstaining from cigarette smoking
Number of subjects: 0
Study 17407593 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine dependent individuals who were not successful in abstaining from cigarette smoking
Number of subjects: 0
Study 17407593 — intervention group
Group type: COMPARATOR
Intervention: Control subjects free from substantial lifetime use of any addictive substance
Number of subjects: 0
Study 15016487 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 2775
Study 15016487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2775
Study 12504395 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol valerate (2 mg, daily for 2 years)
Number of subjects: 1017
Study 12504395 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 2 years)
Number of subjects: 1017
Study 9793663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Number of subjects: 66
Study 9793663 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow aspiration
Number of subjects: 66
Study 9793663 — intervention group
Group type: EXPERIMENTAL
Intervention: Dural puncture
Number of subjects: 66
Study 8558626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (300 mg per kg of body mass)
Number of subjects: 12
Study 8558626 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mg sodium chloride per kg of body mass and 200 mg calcium carbonate per kg of body mass)
Number of subjects: 12
Study 8558626 — intervention group
Group type: COMPARATOR
Intervention: Neither (Control)
Number of subjects: 12
Study 2646504 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 36
Study 2646504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 637277 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudad injection via a 22 gauge Whitacre needle
Number of subjects: 21
Study 637277 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalad or lateral injection via a 22 gauge Whitacre needle
Number of subjects: 21
Study 637277 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose caudally directed injections
Number of subjects: 21
Study 29807715 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index carbohydrates after 55 minutes of aerobic exercise
Number of subjects: 26
Study 29807715 — intervention group
Group type: COMPARATOR
Intervention: High glycemic index carbohydrates after 55 minutes of aerobic exercise
Number of subjects: 26
Study 29264882 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable appliance therapy with electronic sensors for cooperation assessment
Number of subjects: 38
Study 29264882 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers' traits (generalized sense of efficacy, conscientiousness, severity of requirements)
Number of subjects: 38
Study 24703014 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Educator Training Program
Number of subjects: 0
Study 23501141 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal motivations for seeking treatment
Number of subjects: 180
Study 23501141 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational concerns (internal motivator)
Number of subjects: 180
Study 23501141 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal-family concerns (internal motivator)
Number of subjects: 180
Study 23501141 — intervention group
Group type: EXPERIMENTAL
Intervention: General motivations for seeking treatment
Number of subjects: 180
Study 21808934 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity functional exercise program
Number of subjects: 177
Study 21808934 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched drink
Number of subjects: 177
Study 19335909 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-factorial falls prevention program including home exercise and individualised falls prevention strategies
Number of subjects: 0
Study 19335909 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-study evaluating fear of falling, falls, and function over twelve months
Number of subjects: 0
Study 19335909 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-study evaluating residual impairment in gait stability and obstacle crossing
Number of subjects: 0
Study 16404515 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intracoronary brachytherapy (24 Gy)
Number of subjects: 32
Study 16404515 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 32
Study 15389418 — intervention group
Group type: EXPERIMENTAL
Intervention: Dieting protocols (specific protocols not detailed)
Number of subjects: 0
Study 15389418 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of a 1‐ to 2‐week run‐in period
Number of subjects: 0
Study 15389418 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing initial randomized sample size by 10% to 25%
Number of subjects: 0
Study 10885606 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 every 3 weeks
Number of subjects: 43
Study 8813873 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 25 mg
Number of subjects: 80
Study 8813873 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin 10 mg
Number of subjects: 80
Study 8813873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 1919404 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.6% sodium hypochlorite irrigation
Number of subjects: 20
Study 1919404 — intervention group
Group type: COMPARATOR
Intervention: Tap water irrigation
Number of subjects: 20
Study 1919404 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation with either irrigant
Number of subjects: 20
Study 6287931 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone in 1% lidocaine diluent
Number of subjects: 12
Study 6287931 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone in water diluent
Number of subjects: 12
Study 31863206 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (PG) 150 mg per os, 2 doses preoperatively
Number of subjects: 50
Study 31863206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30762399 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy for Cancer‐Related Insomnia (BBT‐CI)
Number of subjects: 71
Study 30762399 — intervention group
Group type: COMPARATOR
Intervention: Healthy-eating control intervention (HEAL)
Number of subjects: 71
Study 28694327 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention based on the 2010 USDA Dietary Guidelines for Americans (DGA) for fruit and vegetable intake for 8 weeks
Number of subjects: 0
Study 26284299 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of fish and mussels (1 kg/week for 26 weeks)
Number of subjects: 102
Study 26284299 — intervention group
Group type: COMPARATOR
Intervention: No intervention (expected to eat less than 300 g of fish and mussels per week)
Number of subjects: 102
Study 24781224 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 62
Study 24781224 — intervention group
Group type: COMPARATOR
Intervention: Atypical neuroleptics (control group)
Number of subjects: 62
Study 23026173 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine plus 3 mg fentanyl
Number of subjects: 60
Study 23026173 — intervention group
Group type: COMPARATOR
Intervention: 0.1% levobupivacaine plus 3 mg fentanyl
Number of subjects: 60
Study 23026173 — intervention group
Group type: COMPARATOR
Intervention: 0.05% levobupivacaine plus 3 mg fentanyl
Number of subjects: 60
Study 19740915 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA (AUC 1700‐2000 ng/ml) + PSL (0.8 mg/kg/day)
Number of subjects: 52
Study 19740915 — intervention group
Group type: COMPARATOR
Intervention: PSL alone (1.0 mg/kg/day)
Number of subjects: 52
Study 18801159 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard arm: total dose 6.0 Gy in single fractions of 1.0 Gy applied twice a week
Number of subjects: 200
Study 18801159 — intervention group
Group type: COMPARATOR
Intervention: Experimental arm: total dose 0.6 Gy in single fractions of 0.1 Gy applied twice a week (acting as a placebo)
Number of subjects: 200
Study 16052085 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole prophylaxis initiation at WHO stage >= 2
Number of subjects: 0
Study 16052085 — intervention group
Group type: COMPARATOR
Intervention: Delayed prophylaxis initiation until WHO stage >= 3
Number of subjects: 0
Study 16052085 — intervention group
Group type: COMPARATOR
Intervention: CD4-based co-trimoxazole initiation (< 500, < 200, < 50 x 10(6) CD4 cells/l)
Number of subjects: 0
Study 16052085 — intervention group
Group type: EXPERIMENTAL
Intervention: Early co-trimoxazole prophylaxis
Number of subjects: 0
Study 11791038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure (10 mmHg wider at baseline)
Number of subjects: 0
Study 11791038 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean pressure
Number of subjects: 0
Study 10509848 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide hydrochloride ophthalmic solution 2% TID
Number of subjects: 194
Study 10509848 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine hydrochloride 2% QID
Number of subjects: 194
Study 8750152 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha + coumarin + cimetidine
Number of subjects: 148
Study 8750152 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha monotherapy
Number of subjects: 148
Study 2709166 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and environmental strategies (three intervention groups with varying levels of potency)
Number of subjects: 0
Study 2709166 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback about health status, persuasive information about risk reduction, and a supportive environment
Number of subjects: 0
Study 2709166 — intervention group
Group type: COMPARATOR
Intervention: Control company
Number of subjects: 0
Study 819597 — intervention group
Group type: EXPERIMENTAL
Intervention: Idoxuridine (given hourly by day and at 2-hr intervals by night for three days)
Number of subjects: 0
Study 819597 — intervention group
Group type: EXPERIMENTAL
Intervention: Human interferon (1.1 X 10(7) international units/ml, applied daily)
Number of subjects: 0
Study 819597 — intervention group
Group type: EXPERIMENTAL
Intervention: Human interferon (given once daily for seven days)
Number of subjects: 0
Study 819597 — intervention group
Group type: COMPARATOR
Intervention: Monkey interferon
Number of subjects: 0
Study 31301442 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-Anchored Annular Closure Device (ACD)
Number of subjects: 550
Study 31301442 — intervention group
Group type: COMPARATOR
Intervention: Discectomy alone (controls)
Number of subjects: 550
Study 28565886 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 300,000 U orally followed by 50,000 U/month for 6 months
Number of subjects: 35
Study 28565886 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 35
Study 25970146 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic khorasan wheat products (bread, pasta, biscuits, crackers)
Number of subjects: 22
Study 25970146 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic khorasan wheat products
Number of subjects: 22
Study 25970146 — intervention group
Group type: COMPARATOR
Intervention: Control wheat products
Number of subjects: 22
Study 23428284 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Belief Model factors
Number of subjects: 1450
Study 23428284 — intervention group
Group type: EXPERIMENTAL
Intervention: Believing themselves at risk for cervical cancer
Number of subjects: 1450
Study 23428284 — intervention group
Group type: EXPERIMENTAL
Intervention: Believing cervical cancer changes life
Number of subjects: 1450
Study 23428284 — intervention group
Group type: EXPERIMENTAL
Intervention: Believing a Pap test is important for staying healthy
Number of subjects: 1450
Study 23428284 — intervention group
Group type: EXPERIMENTAL
Intervention: Not understanding what is done during a Pap test
Number of subjects: 1450
Study 23428284 — intervention group
Group type: EXPERIMENTAL
Intervention: Being scared to know having cervical cancer
Number of subjects: 1450
Study 23428284 — intervention group
Group type: EXPERIMENTAL
Intervention: Taking a Pap test is embarrassing
Number of subjects: 1450
Study 23428284 — intervention group
Group type: EXPERIMENTAL
Intervention: Not being available by doctors at convenient times
Number of subjects: 1450
Study 23428284 — intervention group
Group type: EXPERIMENTAL
Intervention: Having too much time for a test
Number of subjects: 1450
Study 23428284 — intervention group
Group type: EXPERIMENTAL
Intervention: Believing no need for a Pap test when feeling well
Number of subjects: 1450
Study 23428284 — intervention group
Group type: EXPERIMENTAL
Intervention: Being confident in getting a test
Number of subjects: 1450
Study 22094836 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 μg 1,25‐dihydroxy cholecalciferol per capsule, 2 capsules per day)
Number of subjects: 70
Study 22094836 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 70
Study 19018813 — intervention group
Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS) on ear lesions at Location 1 (helix, antihelix, tragus)
Number of subjects: 142
Study 19018813 — intervention group
Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS) on ear lesions at Location 2 (retroauricular)
Number of subjects: 142
Study 19018813 — intervention group
Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS) on ear lesions at Location 3 (conchal bowl, scapha, triangular fossa)
Number of subjects: 142
Study 19018813 — intervention group
Group type: COMPARATOR
Intervention: Control group (NMSC cases from the nose)
Number of subjects: 142
Study 22299644 — intervention group
Group type: COMPARATOR
Intervention: 2000 µg BDP solution with 5 g oral charcoal (OralC)
Number of subjects: 12
Study 22299644 — intervention group
Group type: COMPARATOR
Intervention: 2000 µg BDP solution without oral charcoal (Oral)
Number of subjects: 12
Study 22299644 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,100 µg inhalations from Qvar(®) pMDI (Qvar)
Number of subjects: 12
Study 22299644 — intervention group
Group type: EXPERIMENTAL
Intervention: eight 250 µg inhalations from Clenil(®) pMDI (Clenil)
Number of subjects: 12
Study 22299644 — intervention group
Group type: EXPERIMENTAL
Intervention: Qvar compared with Clenil
Number of subjects: 12
Study 15511598 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obese BED women
Number of subjects: 182
Study 15511598 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese BED women
Number of subjects: 182
Study 15511598 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese non-binge eating women
Number of subjects: 182
Study 15511598 — intervention group
Group type: COMPARATOR
Intervention: Non-obese healthy women
Number of subjects: 182
Study 15511598 — intervention group
Group type: COMPARATOR
Intervention: Bulimic women
Number of subjects: 182
Study 14630756 — intervention group
Group type: COMPARATOR
Intervention: Acetic acid ear drops
Number of subjects: 213
Study 14630756 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid and acetic acid ear drops
Number of subjects: 213
Study 14630756 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid and antibiotic ear drops
Number of subjects: 213
Study 9797832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (400 micrograms/kg)
Number of subjects: 120
Study 9797832 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) (10 mg/kg)
Number of subjects: 120
Study 9797832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9797832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin, DEC, and Placebo
Number of subjects: 120
Study 7653663 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) 50 micrograms, then 50 ng.kg‐1.min‐1
Number of subjects: 7
Study 7653663 — intervention group
Group type: COMPARATOR
Intervention: Saline (as vehicle)
Number of subjects: 7
Study 7653663 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside infusion (0.4 micrograms.kg‐1.min‐1)
Number of subjects: 7
Study 7653663 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF)
Number of subjects: 7
Study 2477204 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 216